A key opinion leader discusses how the medical understanding of heart failure has improved over the years and how it has helped management of disease.
John McMurray, MBChB: We’ve learned a lot about heart failure in the last 2 decades. Even just in the past 5 or 6 years, we’ve made great breakthroughs. Our major advance has been understanding how to treat 1 of 2 major heart failure phenotypes or subgroups. Those are patients who got heart failure with a reduced ejection fraction where the problem is with the contracting and the emptying of the left ventricle of the heart. We now have many pharmacological drugs and treatment devices for that type of heart failure.
What we have not advanced much with is the management of the other major phenotype, which is heart failure with preserved ejection fraction, where the problem is 1 of impaired relaxation and filling of the left ventricle. A pump has to both fill and empty to work properly. We haven’t had any major breakthroughs there, though there has been a conceptual breakthrough in the sense that we realize that heart failure with preserved ejection fraction is probably at least 2 different subtypes of heart failure.
There are individuals who have completely normal ejection fraction where the emptying—the pumping—of the heart is normal, and there are people who have pumping or an ejection fraction that is not normal. But it’s not low, so it’s not in that former heart failure group with reduced ejection fraction. For people who have an ejection fraction below normal but not very low, we are beginning to realize that those patients may constitute a distinct phenotype.
Those individuals may benefit from some of the treatments that we know work in people with a reduced ejection fraction. Maybe we will soon begin to see an expansion of the use some of the treatments we have for heart failure with reduced ejection fraction to a proportion of patients with heart failure with preserved ejection fraction. Some people call those individual patients with heart failure in midrange a mildly reduced ejection fraction.
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Patients With HFpEF May Benefit From Accelerated Cardiac Pacing
August 28th 2025In an observational extension of the myPACE clinical trial, researchers found that a personalized accelerated pacing in patients with heart failure with preserved ejection fraction (HFpEF) and a preexisting physiological pacer saw a slower trend in adverse cardiac events and overall improved health status.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More
Genetics, Comorbidities Associated With Cardiomyopathy and Atrial Fibrillation
August 13th 2025The cause of dilated cardiomyopathy (DCM) can be associated with the presence of the TTN gene combined with preexisting comorbidities like atrial fibrillation, which increase the odds of developing DCM.
Read More